OA10979A - Stable non-hygroscopic crystalline form of n-Än-n-(piperidin-4-yl)butanoyl)-n-ethylglycylÜcompounds - Google Patents
Stable non-hygroscopic crystalline form of n-Än-n-(piperidin-4-yl)butanoyl)-n-ethylglycylÜcompounds Download PDFInfo
- Publication number
- OA10979A OA10979A OA9900037A OA9900037A OA10979A OA 10979 A OA10979 A OA 10979A OA 9900037 A OA9900037 A OA 9900037A OA 9900037 A OA9900037 A OA 9900037A OA 10979 A OA10979 A OA 10979A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- acid
- alkyl
- aryl
- aralkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2428496P | 1996-08-21 | 1996-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10979A true OA10979A (en) | 2001-11-01 |
Family
ID=21819807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA9900037A OA10979A (en) | 1996-08-21 | 1999-02-19 | Stable non-hygroscopic crystalline form of n-Än-n-(piperidin-4-yl)butanoyl)-n-ethylglycylÜcompounds |
Country Status (20)
Country | Link |
---|---|
US (2) | US6153588A (pt) |
EP (1) | EP0923553B1 (pt) |
JP (1) | JP4008499B2 (pt) |
KR (1) | KR20000068229A (pt) |
CN (2) | CN1231659A (pt) |
AP (1) | AP9901462A0 (pt) |
AT (1) | ATE390438T1 (pt) |
AU (1) | AU733591B2 (pt) |
BG (1) | BG63538B1 (pt) |
BR (1) | BR9711340A (pt) |
CA (1) | CA2263647C (pt) |
DE (1) | DE69738601T2 (pt) |
EA (1) | EA001362B1 (pt) |
IL (1) | IL128561A0 (pt) |
NO (1) | NO990721L (pt) |
OA (1) | OA10979A (pt) |
PL (1) | PL331772A1 (pt) |
SK (1) | SK21999A3 (pt) |
WO (1) | WO1998007696A1 (pt) |
ZA (1) | ZA977510B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL128561A0 (en) * | 1996-08-21 | 2000-01-31 | Rhone Poulenc Rorer Pharma | Stable non-hygroscopic crystalline form of N-(N-N-(4-(piperidin-4-YL)butanoyl)-N-ethylglycyl) compounds |
WO1999019294A1 (en) * | 1997-05-14 | 1999-04-22 | Aventis Pharmaceuticals Products Inc. Legal/Patents | Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides |
JP2001519411A (ja) * | 1997-10-10 | 2001-10-23 | アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド | アザシクロアルキルアルカノイルプソイドテトラぺプチドの調製方法 |
WO2000040601A1 (en) * | 1998-12-30 | 2000-07-13 | Aventis Pharmaceuticals Products Inc. | Process for preparing a stable non-hygroscopic crystalline n-[n-[n- piperdin- 4-yl)butanoyl)- n.ethylglycyl]- (l)-aspartyl] -ss-cyclohexylalanine amide |
US20050238834A1 (en) * | 2004-04-21 | 2005-10-27 | Eastman Kodak Company | High modulus label with compliant carrier sheet |
US8021679B2 (en) | 2005-08-25 | 2011-09-20 | Medtronic Vascular, Inc | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore |
US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
US9704557B2 (en) * | 2013-09-25 | 2017-07-11 | Qualcomm Incorporated | Method and apparatus for storing retention time profile information based on retention time and temperature |
CA3009065C (en) | 2015-12-21 | 2022-01-25 | Texas Tech University System | System and method for solution phase gap peptide synthesis |
WO2019217116A1 (en) * | 2018-05-06 | 2019-11-14 | Gap Peptides Llc | Method for solution-phase peptide synthesis |
US12024537B2 (en) | 2018-05-31 | 2024-07-02 | Sederma | Compositions and methods for chemical synthesis |
US11827660B2 (en) | 2019-02-01 | 2023-11-28 | Sederma | Synthesis strategy for gap protecting group |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857508A (en) * | 1987-12-03 | 1989-08-15 | Monsanto Company | Novel platelet-aggregation inhibitor peptide derivatives |
US4992463A (en) * | 1988-07-20 | 1991-02-12 | Monsanto Company | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation |
US5332726A (en) * | 1989-09-29 | 1994-07-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic peptides and pseudopeptides |
US4952562A (en) * | 1989-09-29 | 1990-08-28 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptides and pseudopeptides |
US5064814A (en) * | 1990-04-05 | 1991-11-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Anti-thrombotic peptide and pseudopeptide derivatives |
US5264420A (en) | 1990-09-27 | 1993-11-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
NZ239876A (en) * | 1990-09-27 | 1993-12-23 | Merck & Co Inc | Glycyl-b-alanine derivatives and pharmaceutical compositions thereof. |
US5218138A (en) | 1992-09-02 | 1993-06-08 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1995001336A1 (fr) * | 1993-06-30 | 1995-01-12 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau derive de piperidine |
JP3032297B2 (ja) * | 1993-10-15 | 2000-04-10 | ローヌ‐プーラン ローラー ファーマシューティカルズ インコーポレイテッド | 抗血栓性アザシクロアルキルアルカノイルペプチド及びプソイドペプチド |
US5780590A (en) * | 1993-10-15 | 1998-07-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
US5707994A (en) * | 1993-10-19 | 1998-01-13 | Sumitomo Pharmaceuticals Company, Limited | 2,3-diaminopropionic acid derivative |
IL128561A0 (en) * | 1996-08-21 | 2000-01-31 | Rhone Poulenc Rorer Pharma | Stable non-hygroscopic crystalline form of N-(N-N-(4-(piperidin-4-YL)butanoyl)-N-ethylglycyl) compounds |
JP2001519411A (ja) * | 1997-10-10 | 2001-10-23 | アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド | アザシクロアルキルアルカノイルプソイドテトラぺプチドの調製方法 |
-
1997
- 1997-08-21 IL IL12856197A patent/IL128561A0/xx unknown
- 1997-08-21 EP EP97939488A patent/EP0923553B1/en not_active Expired - Lifetime
- 1997-08-21 BR BR9711340A patent/BR9711340A/pt unknown
- 1997-08-21 ZA ZA9707510A patent/ZA977510B/xx unknown
- 1997-08-21 EA EA199900217A patent/EA001362B1/ru not_active IP Right Cessation
- 1997-08-21 DE DE69738601T patent/DE69738601T2/de not_active Expired - Lifetime
- 1997-08-21 CN CN97198210A patent/CN1231659A/zh active Pending
- 1997-08-21 KR KR1019997001362A patent/KR20000068229A/ko not_active Application Discontinuation
- 1997-08-21 CN CNA021415722A patent/CN1491942A/zh active Pending
- 1997-08-21 AP APAP/P/1999/001462A patent/AP9901462A0/en unknown
- 1997-08-21 PL PL97331772A patent/PL331772A1/xx unknown
- 1997-08-21 AT AT97939488T patent/ATE390438T1/de not_active IP Right Cessation
- 1997-08-21 SK SK219-99A patent/SK21999A3/sk unknown
- 1997-08-21 AU AU41563/97A patent/AU733591B2/en not_active Ceased
- 1997-08-21 CA CA2263647A patent/CA2263647C/en not_active Expired - Fee Related
- 1997-08-21 JP JP51098398A patent/JP4008499B2/ja not_active Expired - Fee Related
- 1997-08-21 WO PCT/US1997/014756 patent/WO1998007696A1/en not_active Application Discontinuation
-
1999
- 1999-02-16 NO NO990721A patent/NO990721L/no unknown
- 1999-02-18 US US09/251,030 patent/US6153588A/en not_active Expired - Fee Related
- 1999-02-19 OA OA9900037A patent/OA10979A/en unknown
- 1999-03-04 BG BG103225A patent/BG63538B1/bg unknown
-
2000
- 2000-08-15 US US09/639,634 patent/US6753409B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NO990721D0 (no) | 1999-02-16 |
CA2263647A1 (en) | 1998-02-26 |
EA001362B1 (ru) | 2001-02-26 |
IL128561A0 (en) | 2000-01-31 |
EP0923553B1 (en) | 2008-03-26 |
JP4008499B2 (ja) | 2007-11-14 |
DE69738601D1 (de) | 2008-05-08 |
US6153588A (en) | 2000-11-28 |
EP0923553A4 (en) | 1999-12-08 |
BG103225A (en) | 2000-01-31 |
NO990721L (no) | 1999-04-20 |
CA2263647C (en) | 2011-02-15 |
WO1998007696A1 (en) | 1998-02-26 |
EP0923553A1 (en) | 1999-06-23 |
CN1231659A (zh) | 1999-10-13 |
KR20000068229A (ko) | 2000-11-25 |
CN1491942A (zh) | 2004-04-28 |
BG63538B1 (bg) | 2002-04-30 |
AP9901462A0 (en) | 1999-03-31 |
AU733591B2 (en) | 2001-05-17 |
ATE390438T1 (de) | 2008-04-15 |
JP2000517305A (ja) | 2000-12-26 |
EA199900217A1 (ru) | 1999-08-26 |
DE69738601T2 (de) | 2009-04-30 |
SK21999A3 (en) | 2000-02-14 |
AU4156397A (en) | 1998-03-06 |
PL331772A1 (en) | 1999-08-02 |
BR9711340A (pt) | 1999-08-17 |
US6753409B1 (en) | 2004-06-22 |
ZA977510B (en) | 1998-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10979A (en) | Stable non-hygroscopic crystalline form of n-Än-n-(piperidin-4-yl)butanoyl)-n-ethylglycylÜcompounds | |
JPH07121955B2 (ja) | アミノ酸誘導体およびその製法 | |
AP904A (en) | Antithrombotic Azacycloalkylalkanoyl peptides and pseudopeptides. | |
JPH0742309B2 (ja) | チアゾリジン誘導体 | |
US5332726A (en) | Antithrombotic peptides and pseudopeptides | |
DE69426897T2 (de) | Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide | |
JPH0670023B2 (ja) | チアゾリジン誘導体 | |
JPH082791B2 (ja) | 健忘症治療剤 | |
US6274705B1 (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
JPH0776211B2 (ja) | ピログルタミン酸誘導体 | |
MXPA99001773A (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
MXPA99001772A (en) | Stable non-hygroscopic crystalline form of n-[n-n-(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl]compounds | |
CZ55199A3 (cs) | Stabilní, nehygroskopická krystalická forma N- [N-[N(4-piperidin-4-yl)butanoyl]-N-ethylgIycyl]ových derivátů | |
CZ55099A3 (cs) | Antitrombotické azacykloalkylalkanoylové peptidy a pseudopeptidy |